Published in Br J Pharmacol on April 03, 2009
Prevention of stress-impaired fear extinction through neuropeptide s action in the lateral amygdala. Neuropsychopharmacology (2012) 1.07
Neuropeptide S receptor induces neuropeptide expression and associates with intermediate phenotypes of functional gastrointestinal disorders. Gastroenterology (2009) 0.99
Intranasally administered neuropeptide S (NPS) exerts anxiolytic effects following internalization into NPS receptor-expressing neurons. Neuropsychopharmacology (2012) 0.93
Neuropeptide S stimulates dopaminergic neurotransmission in the medial prefrontal cortex. J Neurochem (2010) 0.86
Blockade of adenosine A2A receptor counteracts neuropeptide-S-induced hyperlocomotion in mice. Naunyn Schmiedebergs Arch Pharmacol (2009) 0.84
Genetic polymorphism in pathogenesis of irritable bowel syndrome. World J Gastroenterol (2014) 0.82
Modification of caffeine effects on the affect-modulated startle by neuropeptide S receptor gene variation. Psychopharmacology (Berl) (2012) 0.76
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81
The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res Brain Res Rev (2003) 6.09
Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron (2004) 3.61
From waking to sleeping: neuronal and chemical substrates. Trends Pharmacol Sci (2005) 2.59
The neurobiology and control of anxious states. Prog Neurobiol (2003) 2.48
Neuropeptide S-mediated control of fear expression and extinction: role of intercalated GABAergic neurons in the amygdala. Neuron (2008) 2.29
Arousal systems. Front Biosci (2003) 2.07
Noradrenaline modulates transmission at a central synapse by a presynaptic mechanism. Neuron (2007) 2.00
Distribution of neuropeptide S receptor mRNA and neurochemical characteristics of neuropeptide S-expressing neurons in the rat brain. J Comp Neurol (2007) 1.95
Convergent regulation of locus coeruleus activity as an adaptive response to stress. Eur J Pharmacol (2008) 1.82
Pharmacological characterization of human and murine neuropeptide s receptor variants. J Pharmacol Exp Ther (2005) 1.81
Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders. Biol Psychiatry (2002) 1.72
A rapid Percoll gradient procedure for isolation of synaptosomes directly from an S1 fraction: homogeneity and morphology of subcellular fractions. Brain Res (1988) 1.70
Neuropeptide S stimulates the hypothalamo-pituitary-adrenal axis and inhibits food intake. Endocrinology (2006) 1.49
Neuropeptide S is a stimulatory anxiolytic agent: a behavioural study in mice. Br J Pharmacol (2008) 1.46
Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders. Psychopharmacology (Berl) (2008) 1.41
Phosphoinositide lipid second messengers: new paradigms for calcium channel modulation. Neuron (2005) 1.34
Identification of a neuropeptide S responsive circuitry shaping amygdala activity via the endopiriform nucleus. PLoS One (2008) 1.27
Cocaine-induced anxiety: alleviation by diazepam, but not buspirone, dimenhydrinate or diphenhydramine. Behav Pharmacol (2002) 1.24
Peptide S is a novel potent inhibitor of voluntary and fast-induced food intake in rats. Biochem Biophys Res Commun (2005) 1.23
Neuropeptide S: a novel modulator of stress and arousal. Stress (2007) 1.20
Glial plasmalemmal vesicles: a subcellular fraction from rat hippocampal homogenate distinct from synaptosomes. Glia (1993) 1.14
Structure-activity studies on neuropeptide S: identification of the amino acid residues crucial for receptor activation. J Biol Chem (2006) 1.13
Synaptosomes still viable after 25 years of superfusion. Neurochem Res (2000) 1.13
Anxiolytic-like effect of neuropeptide S in the rat defensive burying. Peptides (2008) 1.08
5-Hydroxytryptamine pathways in anxiety and its treatment. Pharmacol Ther (1995) 0.99
Repeated cannabinoid administration increases indices of noradrenergic activity in rats. Pharmacol Biochem Behav (2007) 0.97
Noradrenergic facilitation of shock-probe defensive burying in lateral septum of rats, and modulation by chronic treatment with desipramine. Prog Neuropsychopharmacol Biol Psychiatry (2006) 0.96
The effects of neuropeptide S on ethanol drinking and other related behaviors in alcohol-preferring and -nonpreferring rats. Alcohol Clin Exp Res (2008) 0.95
Synthesis and biological activity of human neuropeptide S analogues modified in position 2. J Med Chem (2008) 0.95
Anorexigenic effects of central neuropeptide S involve the hypothalamus in chicks (Gallus gallus). Comp Biochem Physiol A Mol Integr Physiol (2007) 0.93
A new approach to the light/dark test procedure in mice. Pharmacol Biochem Behav (1998) 0.89
Glutamate and anxiety disorders. Curr Psychiatry Rep (2007) 0.87
Presynaptic inhibition by clonidine of neurotransmitter amino acid release in various brain regions. Eur J Pharmacol (1992) 0.87
Glutamate release in human cerebral cortex and its modulation by 5-hydroxytryptamine acting at h 5-HT1D receptors. Br J Pharmacol (1998) 0.87
Functional pharmacology in human brain. Pharmacol Rev (2006) 0.86
Mechanisms of glutamate release elicited in rat cerebrocortical nerve endings by 'pathologically' elevated extraterminal K+ concentrations. J Neurochem (2007) 0.86
The orphanin FQ/nociceptin knockout mouse: a behavioral model for stress responses. Neuropeptides (2002) 0.85
Functional switch from facilitation to inhibition in the control of glutamate release by metabotropic glutamate receptors. J Biol Chem (1998) 0.85
Molecular manipulations as tools for enhancing our understanding of 5-HT neurotransmission. Trends Pharmacol Sci (1999) 0.84
Unexpected inhibitory regulation of glutamate release from rat cerebrocortical nerve terminals by presynaptic 5-hydroxytryptamine-2A receptors. J Neurosci Res (2006) 0.80
Inhibitory presynaptic 5-hydroxytryptamine(2A) receptors regulate evoked glutamate release from rat cerebellar mossy fibers. J Pharmacol Exp Ther (2001) 0.79
Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study. J Clin Endocrinol Metab (2015) 2.41
Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab (1994) 2.05
Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br J Pharmacol (2000) 1.97
Neuropeptide S is a stimulatory anxiolytic agent: a behavioural study in mice. Br J Pharmacol (2008) 1.46
Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy. Immunol Today (1996) 1.45
A new selective antagonist of the nociceptin receptor. Br J Pharmacol (1998) 1.41
Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide. J Med Chem (1997) 1.36
Sudden death from pulmonary thromboembolism: chronobiological aspects. Eur Heart J (1992) 1.35
Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer (2006) 1.33
RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. J Clin Endocrinol Metab (2001) 1.31
Post-Chernobyl thyroid carcinoma in Belarus children and adolescents: comparison with naturally occurring thyroid carcinoma in Italy and France. J Clin Endocrinol Metab (1997) 1.25
Presence and bronchomotor activity of protease-activated receptor-2 in guinea pig airways. Am J Respir Crit Care Med (2000) 1.24
Subclinical hypothyroidism in obese patients: relation to resting energy expenditure, serum leptin, body composition, and lipid profile. Obes Res (2001) 1.22
Brain auditory activation measured by near-infrared spectroscopy (NIRS) in neonates. Pediatr Res (2001) 1.18
Characterization of [Nphe(1)]nociceptin(1-13)NH(2), a new selective nociceptin receptor antagonist. Br J Pharmacol (2000) 1.18
Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth (2009) 1.15
Urodynamic and clinical evidence of acute inhibitory effects of intravesical nociceptin/orphanin FQ on detrusor overactivity in humans: a pilot study. J Urol (2001) 1.12
High prevalence of a rare hepatitis C virus in patients treated in the same hemodialysis unit: evidence for nosocomial transmission of HCV. Kidney Int (1995) 1.09
Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies. Naunyn Schmiedebergs Arch Pharmacol (1999) 1.08
Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay. Br J Pharmacol (1998) 1.07
Structure-activity study of the nociceptin(1-13)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist. J Med Chem (1998) 1.02
Function of negative charge in the "address domain" of deltorphins. J Med Chem (1991) 1.02
Nociceptin/orphanin FQ receptor ligands. Peptides (2000) 1.02
The mouse vas deferens: a pharmacological preparation sensitive to nociceptin. Eur J Pharmacol (1996) 1.00
Further studies on nociceptin-related peptides: discovery of a new chemical template with antagonist activity on the nociceptin receptor. J Med Chem (2000) 1.00
Effect of the three-dimensional structure on the deamidation reaction of ribonuclease A. J Pept Res (1999) 0.98
Effects of vasoactive agents in healthy and diseased human saphenous veins. J Vasc Surg (1998) 0.98
Leptin plasma concentrations are dependent on body fat distribution in obese patients. Int J Obes Relat Metab Disord (2000) 0.98
Prevalence of undiagnosed coeliac syndrome in osteoporotic women. J Intern Med (2001) 0.95
Interaction of deltorphin with opioid receptors: molecular determinants for affinity and selectivity. Peptides (1993) 0.95
The A19G polymorphism in the 5' untranslated region of the human obese gene does not affect leptin levels in severely obese patients. J Clin Endocrinol Metab (2000) 0.94
Perspectives of protein kinase C (PKC) inhibitors as anti-cancer agents. Mini Rev Med Chem (2009) 0.94
Characterization of the locomotor activity-inhibiting effect of nociceptin/orphanin FQ in mice. Naunyn Schmiedebergs Arch Pharmacol (2001) 0.94
Selective opioid dipeptides. Biochem Biophys Res Commun (1994) 0.94
Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test. Eur J Neurosci (2003) 0.92
In vitro and in vivo pharmacological profile of UFP-512, a novel selective delta-opioid receptor agonist; correlations between desensitization and tolerance. Br J Pharmacol (2007) 0.91
What peptides these deltorphins be. Prog Neurobiol (1999) 0.91
Nociceptin and the ORL-1 ligand [Phe1psi (CH2-NH)Gly2]nociceptin(1-13)NH2 exert anti-opioid effects in the Freund's adjuvant-induced arthritic rat model of chronic pain. Br J Pharmacol (1999) 0.91
Mortality rate and outcome factors in mixed cryoglobulinaemia: the impact of hepatitis C virus. Scand J Rheumatol (2010) 0.91
Circadian variation in attempted suicide by deliberate self poisoning. BMJ (1994) 0.91
Simian virus 40-like DNA sequences in human papillary thyroid carcinomas. Oncogene (1998) 0.90
Total body water estimation using bioelectrical impedance: a meta-analysis of the data available in the literature. Acta Diabetol (2003) 0.89
[Nphe(1)]nociceptin-(1-13)-NH(2) antagonizes nociceptin effects in the mouse colon. Eur J Pharmacol (1999) 0.89
Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111. Br J Pharmacol (2013) 0.88
The nociceptin/orphanin FQ receptor antagonist, [Nphe1]NC(1-13)NH2, potentiates morphine analgesia. Neuroreport (2000) 0.88
Antidepressant-like effects of the nociceptin/orphanin FQ receptor antagonist UFP-101: new evidence from rats and mice. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.88
[Dmt1]N/OFQ(1-13)-NH2: a potent nociceptin/orphanin FQ and opioid receptor universal agonist. Br J Pharmacol (2013) 0.88
EXIT procedure in a twin gestation and review of the literature. Am J Perinatol (2001) 0.88
Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone. Bone (2006) 0.87
In vitro and in vivo pharmacological characterization of nociceptin/orphanin FQ tetrabranched derivatives. Br J Pharmacol (2014) 0.87
Expression of thyrotropin receptor (TSH-R), thyroglobulin, thyroperoxidase, and calcitonin messenger ribonucleic acids in thyroid carcinomas: evidence of TSH-R gene transcript in medullary histotype. J Clin Endocrinol Metab (1994) 0.86
Na+ mechanism of delta-opioid receptor induced protection from anoxic K+ leakage in the cortex. Cell Mol Life Sci (2009) 0.86
Solution and solid-state structure of the diketopiperazine of tyrosyl-tetrahydroisoquinoline-3-carboxylic acid. Int J Pept Protein Res (1995) 0.86
Synthesis and pharmacological activity of dermorphin and its N-terminal sequences. Int J Pept Protein Res (1982) 0.86
Pharmacology of [Tyr1]nociceptin analogs: receptor binding and bioassay studies. Naunyn Schmiedebergs Arch Pharmacol (1999) 0.86
Pharmacological profile of hemokinin 1: a novel member of the tachykinin family. Life Sci (2002) 0.86
Expression of p21 ras protein as a prognostic factor in papillary thyroid cancer. Eur J Cancer (1994) 0.86
Pharmacological characterization of nociceptin receptor: an in vitro study. Can J Physiol Pharmacol (1997) 0.86
RET proto-oncogene mutations in thyroid carcinomas: clinical relevance. J Endocrinol Invest (2000) 0.85
Cardiovascular effects of nociceptin in unanesthetized mice. Hypertension (1999) 0.85
FR 173657: a new, potent, nonpeptide kinin B2 receptor antagonist. An in vitro study. Hypertension (1997) 0.85
Pycnodysostosis: review and case report. Minerva Stomatol (2014) 0.85
Structure/function relationships in the hemoglobin components from moray (Muraena helena). Eur J Biochem (1995) 0.85
Studies on the antinociceptive effect of [Nphe1]nociceptin(1-13)NH2 in mice. Neurosci Lett (2001) 0.84
Identification of the Cys634-->Tyr mutation of the RET proto-oncogene in a pedigree with multiple endocrine neoplasia type 2A and localized cutaneous lichen amyloidosis. J Endocrinol Invest (1994) 0.84
Candida albicans infection of gastric ulcer frequency and correlation with medical treatment. Results of a multicenter study. Dig Dis Sci (1985) 0.84
Post-transcriptional regulation of MHC class II expression in human T cells. Cell Immunol (1992) 0.84
MEN 11270, A novel selective constrained peptide antagonist with high affinity at the human B2 kinin receptor. J Pharmacol Exp Ther (1999) 0.84
Parallel bioassay of 39 tachykinins on 11 smooth muscle preparations. Structure and receptor selectivity/affinity relationship. Peptides (2000) 0.83
B chromosomes in Crustacea Decapoda. Cytogenet Genome Res (2004) 0.82
Dermorphin inhibits spinal nociceptive flexion reflex in humans. Brain Res (1986) 0.82
Proton magnetic resonance studies on dermorphin and its peptide fragments. Biopolymers (1984) 0.82
The novel delta opioid receptor agonist UFP-512 dually modulates motor activity in hemiparkinsonian rats via control of the nigro-thalamic pathway. Neuroscience (2009) 0.82
Nociceptin receptor binding in mouse forebrain membranes: thermodynamic characteristics and structure activity relationships. Br J Pharmacol (1998) 0.82
Disappearance rate of serum calcitonin after total thyroidectomy for medullary thyroid carcinoma. Int J Biol Markers (1994) 0.82
Polyclonal origin of medullary carcinoma of the thyroid in multiple endocrine neoplasia type 2. Hum Genet (1997) 0.82
Endogenous nociceptin signaling and stress-induced analgesia. Neuroreport (2001) 0.82
Stereospecificity of amino acid side chains in deltorphin defines binding to opioid receptors. J Med Chem (1992) 0.82
Nociceptin receptor activation inhibits tachykinergic non adrenergic non cholinergic contraction of guinea pig isolated bronchus. Life Sci (1999) 0.81
New delta-opioid antagonists as pharmacological probes. Trends Pharmacol Sci (1998) 0.81
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer. Endocr Relat Cancer (2011) 0.81
Structure-activity studies of the Phe(4) residue of nociceptin(1-13)-NH(2): identification of highly potent agonists of the nociceptin/orphanin FQ receptor. J Med Chem (2001) 0.81
Synthesis and receptor binding analysis of dermorphin hepta-, hexa- and pentapeptide analogues. Evidence for one- and two-side binding models for the mu-opioid receptor. Int J Pept Protein Res (1993) 0.81
Thyroid-stimulating hormone and prolactin responses to thyrotropin-releasing hormone in juvenile obesity before and after hypocaloric diet. J Endocrinol Invest (1995) 0.81
Acid catalysis in the formation of dioxopiperazines from peptides containing tetrahydroisoquinoline-3-carboxylic acid at position 2. Int J Pept Protein Res (1995) 0.80
An interdisciplinary approach to a survey on dental caries in a group of 3-year-olds in Ascoli Piceno (Italy). Eur J Paediatr Dent (2010) 0.80
Nociceptin binding sites in frog (Rana esculenta) brain membranes. Biochem Biophys Res Commun (1999) 0.80
Design of mu selective opioid dipeptide antagonists. FEBS Lett (1997) 0.80
[The EX-utero Intrapartum Technique (EXIT) procedure in Italy]. Minerva Ginecol (2001) 0.80
Circadian differences in the individual sensitivity to opiate overdose. Crit Care Med (2001) 0.80
Major and 5S ribosomal sequences of the largemouth bass Micropterus salmoides (Perciformes, Centrarchidae) are localized in GC-rich regions of the genome. Chromosome Res (2000) 0.80
Opioid receptor selectivity reversal in deltorphin tetrapeptide analogues. Biochem Biophys Res Commun (1991) 0.80
Emerging evidence for neurotensin receptor 1 antagonists as novel pharmaceutics in neurodegenerative disorders. Mini Rev Med Chem (2009) 0.80
Opioid receptor selectivity alteration by single residue replacement: synthesis and activity profile of [Dmt1]deltorphin B. Eur J Pharmacol (1996) 0.80
Opioid pseudopeptides containing heteroaromatic or heteroaliphatic nuclei. Peptides (2000) 0.80
Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations. Surgery (1995) 0.80
Distribution and pharmacological properties of the GABAA/benzodiazepine/chloride ionophore receptor complex in the brain of the fish Anguilla anguilla. J Neurochem (1989) 0.79